Paul Rennie interviewed on Marcus Today Podcast., page-22

Couple of quick notes. They saw the cash picture quite clearly, and fully expect PAR to have to 'rattle the tin' with a CR at some point (mentioned 5 quarters of cash on the books, so probably end of this year). By saying that, though, they omitted any chance of PAR cutting a deal for MPS. See Ox's excellent post just above. So that's major potential upside on the position they formed, if it were to eventuate.

The other thing that stood out for me wasn't anything analytical. It was when Henry said 'Pentosan Polysulfate Sodium' the host quipped that he thinks he deserved a round of applause just for pronouncing it. This is how far back the 99.9% of the market in Australia is, never mind overseas. We shouldn't forget how intimidating biotech is for many investors. Many just ignore the sector because all that jargon, terminology, multi-syllabic drug nomenclature, Phases this and that with data that's hard to understand, and a high chance of being burned. Even people who live and breathe the markets in Australia don't know anymore than having a passing acquaintance with the $PAR ticker.

It just hammers home that what is happening with this company is flying resoundingly under the radar of almost everyone.